Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Aadil Ahmed Memon, Haiping Zhang, Ye Gu, Qian Luo, Jiajun Shi, Zixin Deng, Jian Ma & Wei Ma. (2017) EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma. OncoTargets and Therapy 10, pages 4607-4613.
Read now
Read now
Di Liu, Wen Xu, Xi Ding, Yang Yang, Yanlin Lu, Ke Fei & Bo Su. (2017) Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy. Cancer Biology & Therapy 18:12, pages 948-957.
Read now
Read now
Articles from other publishers (17)
Ángela Marrugal, Irene Ferrer, Álvaro Quintanal-Villalonga, Laura Ojeda, María Dolores Pastor, Ricardo García-Luján, Amancio Carnero, Luis Paz-Ares & Sonia Molina-Pinelo. (2023) Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy. International Journal of Molecular Sciences 24:18, pages 13830.
Crossref
Crossref
Hao Wang, Yang He, Weipeng Zhao & Zhongsheng Tong. (2022) Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review. Anti-Cancer Drugs 33:8, pages 773-777.
Crossref
Crossref
Sitanshu S. Singh, Achyut Dahal, Leeza Shrestha & Seetharama D. Jois. (2020) Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. Current Medicinal Chemistry 27:32, pages 5274-5316.
Crossref
Crossref
Marrugal, Ferrer, Pastor, Ojeda, Quintanal-Villalonga, Carnero, Molina-Pinelo & Paz-Ares. (2019) Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells 8:8, pages 806.
Crossref
Crossref
Verena Schildgen & Oliver Schildgen. 2019. Companion and Complementary Diagnostics. Companion and Complementary Diagnostics
413
427
.
Suman Chatterjee & Timothy F. Burns. 2019. Heat Shock Proteins in Signaling Pathways. Heat Shock Proteins in Signaling Pathways
359
395
.
Shudi Yang, Zhaoxiang Ren, Mengtian Chen, Ying Wang, Bengang You, Weiliang Chen, Chenxi Qu, Yang Liu & Xuenong Zhang. (2017) Nucleolin-Targeting AS1411-Aptamer-Modified Graft Polymeric Micelle with Dual pH/Redox Sensitivity Designed To Enhance Tumor Therapy through the Codelivery of Doxorubicin/TLR4 siRNA and Suppression of Invasion. Molecular Pharmaceutics 15:1, pages 314-325.
Crossref
Crossref
Kalliopi TsakiriVassiliki KotoulaSotirios LakisJudith MüllerFlorentia FostiraMattheos BobosProdromos HytiroglouGeorge Fountzilas. (2017)
Crizotinib Failure in a
TPM4-ALK
–Rearranged Inflammatory Myofibroblastic Tumor With an Emerging
ALK
Kinase Domain Mutation
. JCO Precision Oncology:1, pages 1-7.
Crossref
Crossref
Suman Chatterjee, Eric H.-B. Huang, Ian Christie, Brenda F. Kurland & Timothy F. Burns. (2017)
Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in
KRAS-
Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
. Molecular Cancer Therapeutics 16:5, pages 793-804.
Crossref
Crossref
Shuting Ding, Nan Liu, Huanyu Zhao, Guiyang Jiang, Xiupeng Zhang & Enhua Wang. (2016) Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer. Tumor Biology 37:8, pages 10917-10922.
Crossref
Crossref
Verena Schildgen, Jessica Lüsebrink, Oliver Schildgen, Erich Stoelben & Michael Brockmann. (2016) Epidemiology of driver mutations in lung cancer in a German tertiary hospital in patients with testing indication. Personalized Medicine 13:4, pages 315-323.
Crossref
Crossref
Annkathrin Hanssen, Jenny Wagner, Tobias M. Gorges, Aline Taenzer, Faik G. Uzunoglu, Christiane Driemel, Nikolas H. Stoecklein, Wolfram T. Knoefel, Sebastian Angenendt, Siegfried Hauch, Djordje Atanackovic, Sonja Loges, Sabine Riethdorf, Klaus Pantel & Harriet Wikman. (2016) Characterization of different CTC subpopulations in non-small cell lung cancer. Scientific Reports 6:1.
Crossref
Crossref
Till Plönes, Walburga Engel-Riedel, Erich Stoelben, Christina Limmroth, Oliver Schildgen & Verena Schildgen. (2016) Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. Journal of Personalized Medicine 6:1, pages 3.
Crossref
Crossref
Saveri Bhattacharya, Mark A. Socinski & Timothy F. Burns. (2015)
KRAS
mutant lung cancer: progress thus far on an elusive therapeutic target
. Clinical and Translational Medicine 4:1.
Crossref
Crossref
Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle, Youssouf Oulkhouir, Martin Schuler, Alessandra Curioni-Fontecedro, Benjamin Huret, Mallorie Kerjouan, Sebastian Michels, Georg Pall, Sacha Rothschild, Gerald Schmid-Bindert, Matthias Scheffler, Rémi Veillon, Luciano Wannesson, Joachim Diebold, Gérard Zalcman, Thomas Filleron & Julien Mazières. (2015) Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. Journal of Thoracic Oncology 10:10, pages 1451-1457.
Crossref
Crossref
Li-Min Xu, Li-Qin Li, Jing Li, Hong-Wei Li, Qi-Bin Shen, Jin-Liang Ping, Zhi-Hong Ma, Jing Zhong & Li-Cheng Dai. (2015) Upregulation of MiR-1280 Expression in Non-small Cell Lung Cancer Tissues. Chinese Medical Journal 128:5, pages 670-673.
Crossref
Crossref
Jing Wang, Yuhai Zhang, Shudi Xu, Weijie Li, Zhangqin Chen, Zhe Wang, Xinpeng Han, Yiling Zhao & Shengqing Li. (2015) Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients. Oncology Letters.
Crossref
Crossref